|Treatments:||Biologic therapy||Hospital:||Civil Hospital of Vimercate|
Patients: 179 patients with intermediate or advanced stage liver cancer started this study. These patients (123 men and 56 women; mean age 64.9 years) were not eligible for other therapies because of their intermediate or advanced hepatocellular carcinoma.
Treatment: The patients were randomly assigned to either receive no treatment, or to receive Stem Cell Differentiation Stage Factors derived from Zebra Fish embryos.
Toxicity: Diarrhea, pain in calves, and itching were all reported but no grades were given.
Results: Overall median survival was not reported.
Correspondence: Pier Mario Biava